title: Allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia following nonmyeloablative conditioning using 200-cGy total body irradiation and fludarabine.
authors.forename: L P
authors.initials: LP
authors.lastname: Koh
authors.forename: M B C
authors.initials: MB
authors.lastname: Koh
authors.forename: H Y
authors.initials: HY
authors.lastname: Ng
authors.forename: W Y K
authors.initials: WY
authors.lastname: Hwang
authors.forename: Y T
authors.initials: YT
authors.lastname: Goh
authors.forename: Y C
authors.initials: YC
authors.lastname: Linn
authors.forename: H J
authors.initials: HJ
authors.lastname: Ng
authors.forename: C T H
authors.initials: CT
authors.lastname: Chuah
authors.forename: K W
authors.initials: KW
authors.lastname: Tan
authors.forename: Y S M
authors.initials: YS
authors.lastname: Loh
authors.forename: D C L
authors.initials: DC
authors.lastname: Tan
authors.forename: P H C
authors.initials: PH
authors.lastname: Tan
authors.forename: P H C
authors.initials: PH
authors.lastname: Tan
mesh_terms: D000328:Adult; D000741:Anemia, Aplastic / Q000150:complications / Q000401:mortality / Q000628:therapy*; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000209:etiology / Q000401:mortality / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000008:administration & dosage*; D036102:Peripheral Blood Stem Cell Transplantation / Q000401:mortality; D012074:Remission Induction; D012189:Retrospective Studies; D012720:Severity of Illness Index; D019172:Transplantation Conditioning / Q000379:methods / Q000401:mortality; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D014916:Whole-Body Irradiation
chemical_list: D019653:Myeloablative Agonists; D014740:Vidarabine; C024352:fludarabine